Antimicrobial silver compounds for seed treatment
Innovotech introduces a novel antimicrobial silver compound, AgreGuard, complexed with iodine for effective microbial control in seed treatment. It is cost-effective, easy to apply, and has shown promise in early trials with multiple crops.
Overview
Innovotech Labs Corporation has developed an innovative antimicrobial silver compound named AgreGuard, designed for seed treatment. This compound, complexed with iodine, provides a broad-spectrum antimicrobial effect by effectively targeting bacteria, biofilms, and fungi. AgreGuard is not only highly effective but also cost-efficient, requiring minimal quantities for application. Initial studies across various crops have demonstrated its potential without affecting plant health or germination negatively.
Technical specifications
- Composition: Silver compound complexed with iodine (Ag5IO6).
- Formulations: Available in both powder and water-soluble variants, enhancing application flexibility.
- Application: Easily applied to seeds, ensuring efficient coverage and protection.
- Benefits: Cost-effective production, broad-spectrum microorganism control, no adverse effects on plant growth.
Technology readiness level
The technology has reached Technology Readiness Level 5. It has been tested in relevant environments, and further trials are planned. Small-scale production is feasible for additional testing under development agreements, with the potential for scaling up for commercial use.
About Innovotech Labs Corporation
Innovotech Labs Corporation is a contract research organization and a wholly owned subsidiary of the diversified Canadian technology company Innovotech Inc. The organization provides specialized laboratory services, including proprietary devices for antimicrobial testing designed for applications such as medical devices like catheters, implants, and wound dressings. Beyond testing, the company is involved in commercializing antimicrobial silver solutions, including the development of silver compounds like InnovoSIL-1. In January 2026, the company amalgamated with Keystone Labs Inc. to form a single entity, continuing to operate as Innovotech Labs Corporation under the broader Innovotech Inc. corporate structure, which is listed on the TSX Venture Exchange.
These services and products are essential for medical device manufacturers and industrial clients needing to navigate evolving international regulatory standards regarding biofilm formation, proliferation, and microbial translocation. By providing specialized technical expertise and developing innovative antimicrobial solutions, the company assists clients in reducing infections and improving health outcomes. Their laboratory operations are accredited to ISO/IEC 17025:2017 standards, ensuring technical competence for their defined scope of services. The company also engages in research and development supported by government initiatives, such as the NRC IRAP, to expand its technical capabilities and address complex challenges in antimicrobial product development.
delivered to your inbox.